Twice-daily versus Once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis

Pediatric Dermatology

Volumn 26, Issue 5, 2009, Pages 551-558

  Ruer Mulard, Mireille ^a   Aberer, Werner ^b   Gunstone, Anthony ^c   Kekki, Outi Maria ^d   Estebaranz, Jose Luis López ^e   Vertruyen, André ^f   Guettner, Achim ^g   Hultsch, Thomas ^g  

^a Centre Médical   (France)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Staploe Medical Centre   (United Kingdom)

^d Koskiklinikka ^*  (Finland)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^f Sint Vincentiusziekenhuis   (Belgium)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; PIMECROLIMUS;

APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE INFECTION; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; ARTICLE; ATOPIC DERMATITIS; BRONCHITIS; CHICKENPOX; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; EXFOLIATIVE DERMATITIS; FEMALE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RECURRENT DISEASE; REMISSION; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; TACROLIMUS; TREATMENT OUTCOME;

EID: 70350011824     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2009.00981.x     Document Type: Article

References (25)

1. Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003 361 : 151 160. (Pubitemid 36092023)
2. Boguniewicz M. Update on atopic dermatitis: insights into pathogenesis and new treatment paradigms. Allergy Asthma Proc 2004 25 : 279 282.
3. Breuer K, Werfel T, Kapp A. Allergic manifestations of skin diseases - atopic dermatitis. Chem Immunol Allergy 2006 91 : 76 86.
4. Ellis C, Luger T, Abeck D et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003 148 (Suppl. 63 3 10.
5. Stuetz A, Baumann K, Grassberger M et al. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol 2006 141 : 199 212.
6. Queille-Roussel C, Paul C, Duteil C et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double blind controlled study. Br J Dermatol 2001 144 : 507 513.
7. Graham-Brown RAC, Grassberger M. Pimecrolimus: a review of preclinical and clinical data. Int J Clin Pract 2003 57 : 319 327.
8. Meurer M, Folster-Holst R, Wozel G et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002 205 : 271 277.
9. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002 46 : 495 504.
10. Kapp A, Papp K, Bingham A et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002 110 : 277 284.
11. Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 110 : e2.
12. Luger TA, Lahfa M, Fölster-Holst R et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatol Treat 2004 15 : 169 178.
13. Papp KA, Werfel T, Fölster-Holst R et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005 52 : 240 246.
14. Lakhanpaul M, Davies T, Allen BR et al. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%. Exp Dermatol 2006 15 : 138 141.
15. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005 211 : 174 187. (Pubitemid 41160263)
16. Langley RGB, Luger TA, Cork MJ et al. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology 2007 215 (Suppl. 1 27 44.
17. Büchau AS, Schauber J, Hultsch T et al. Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J Invest Dermatol 2008 128 : 2646 2654.
18. Siegfried E, Korman N, Molina C et al. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis. J Dermatol Treat 2006 17 : 143 150.
19. Van Leent EJ, Graber M, Thurston M et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998 134 : 805 809.
20. Hanifin JM, Thurston M, Omoto M et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001 10 : 11 18.
21. Cox DR. Regression models and life tables. J R Stat Soc Series B 1972 34 : 187 220.
22. Ling M, Gottlieb A, Pariser D et al. A randomized study on the safety, absorption and efficacy of pimecrolimus cream 1% applied twice daily or four times daily in patients with atopic dermatitis. J Dermatol Treat 2005 16 : 142 148.
23. DiMatteo MR. Patient adherence to pharmacotherapy: the importance of effective communication. Formulary 1995 30 : 596 602.
24. McAlister RO, Tofte SJ, Doyle JJ et al. Patient and physician perspectives vary on atopic dermatitis. Cutis 2002 69 : 461 466.
25. Paller AS, McAlister RO, Doyle JJ et al. Perception of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr 2002 41 : 323 332.